Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemziviptadil Open Label Extension in Pulmonary Arterial Hypertension
NCT03795428Phase 2Terminated
- Sponsor
- PhaseBio Pharmaceuticals
- Start
- Apr 2019
- Primary completion
- Jan 2022
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of pemziviptadil in pulmonary arterial hypertension (PAH), sponsored by PhaseBio Pharmaceuticals. Started Apr 2019; status: terminated.
02
Drugs
pemziviptadil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03795428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03795428.